Connect with us

Lifestyle

New Weight-Loss Injection Delivers 20% Weight Reduction

Published

on

New Weight-Loss Injection Delivers 20% Weight Reduction
Share This On:

A weekly injection that combines two medicines helped adults lose around one-fifth of their body weight in a major clinical trial. The findings suggest that even lower doses of the combination could offer meaningful weight loss.

The experimental treatment, called CagriSema, brings together semaglutide and cagrilintide. Both act on the body’s signals for hunger and fullness, although they work in different ways. The goal is to help people feel satisfied with less food.

Obesity is more than a question of appearance. It can raise the risk of high blood pressure, heart disease and breathing problems during sleep. Losing weight can improve some of these health problems, but keeping weight off is often difficult.

ALSO READ:  These Foods Give More Iron And Support Overall Well-being

The new study, called REDEFINE 9, was published in The Lancet Diabetes & Endocrinology in November 2026. Researchers followed 309 adults for 68 weeks at 24 medical centers across five countries. All had obesity, or were overweight with a related health condition, and none had diabetes.

Participants were randomly assigned to one of three groups. Two groups received different lower doses of CagriSema, while the third received an injection without active medicine. Everyone also received advice about food and physical activity.

Among people who stayed on treatment, the average weight loss was 20.7% in the higher-dose group and 21.0% in the lower-dose group. The comparison group lost 2.0% on average. When researchers counted everyone, including those who stopped treatment, the average losses were 19.4%, 18.6% and 4.6%.

ALSO READ:  Amazing Health Benefits Of Unripe Plantain

About half of those taking CagriSema lost at least 20% of their starting weight. Their waist measurements also fell by roughly 17 centimeters, compared with about 4 centimeters in the comparison group.

The similar results from both doses are encouraging. They raise the possibility that doctors might one day choose among doses based on patients’ needs rather than assuming more medicine always produces better results.

However, this was a relatively small study, and its participants were mostly women. It did not establish how well the treatment works for everyone or what happens after many years. CagriSema remains an investigational treatment, so larger and longer studies are needed before firm conclusions can be drawn.

Share This On:
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending